BiotechTube

RP-L301

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pyruvate Kinase Deficiency

Conditions

Pyruvate Kinase Deficiency

Trial Timeline

Aug 1, 2024 → Jan 1, 2029

NCT ID
NCT06422351

About RP-L301

RP-L301 is a phase 2 stage product being developed by Rocket Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06422351. Target conditions include Pyruvate Kinase Deficiency.

What happened to similar drugs?

1 of 6 similar drugs in Pyruvate Kinase Deficiency were approved

Approved (1) Terminated (0) Active (5)
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
🔄MitapivatAgios PharmaceuticalsPhase 3
🔄Placebo + AG-348Agios PharmaceuticalsPhase 3
✅MitapivatAgios PharmaceuticalsApproved
🔄AG-348Agios PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06422351Phase 2Recruiting
NCT04105166Phase 1Completed

Competing Products

9 competing products in Pyruvate Kinase Deficiency

See all competitors
ProductCompanyStageHype Score
TriheptanoinUltragenyx PharmaceuticalPhase 1
30
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
Mitapivat + Mitapivat-matching placeboAgios PharmaceuticalsPhase 3
38
MitapivatAgios PharmaceuticalsPhase 3
34
Placebo + AG-348Agios PharmaceuticalsPhase 3
34
MitapivatAgios PharmaceuticalsApproved
44
AG-348Agios PharmaceuticalsPhase 3
34
AG-348Agios PharmaceuticalsPhase 2
29
RP-L301Rocket PharmaceuticalsPhase 1
19